Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)

The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or without (Group 2) HIPEC with Mitomycin-C.

Trial Details

NCT ID
NCT05250648
Phase
PHASE4
Sponsor
Hospital Universitario de Fuenlabrada
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
  • complete cytoreductive surgery without HIPEC
Locations (sample)
  • Elche, Alicante, Spain|38.26218,-0.70107
  • Almería, Almería, Spain|36.83814,-2.45974
  • Badajoz, Badajoz, Spain|38.87789,-6.97061
  • Sant Joan Despí, Barcelona, Spain|41.36718,2.0574
  • Castellon, Castellón, Spain|39.98567,-0.04935

Key Eligibility Criteria

  • Histologically confirmed colon adenocarcinoma, except signet ring cell carcinomas (those with \> 50% of the tumor composed of these cells, which co…
  • Absence of previously treated or current extraperitoneal metastases, including distant lymphadenopathy (retroperitoneal, mediastinal, etc), liver m…
  • Synchronous or metachronous peritoneal metastasis of mild to moderate volume, with a PCI ≤ 20 (Appendix 2) (intraoperative confirmation).
  • Macroscopically complete surgical cytoreduction CCS-0 (intraoperative confirmation).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →